Baraclude is a prescription antiviral medication that contains entecavir as its active ingredient. Entecavir belongs to the nucleoside analogue class of antivirals and is used to treat chronic hepatitis B infection. In Hong Kong, Baraclude is marketed as a 0.5 mg oral pill and is regulated by the Hong Kong Department of Health under the Pharmacy and Poisons Ordinance.
Entecavir is a reverse-transcriptase inhibitor. After oral ingestion, it is absorbed into the bloodstream and taken up by liver cells infected with hepatitis B virus (HBV). Inside the cell, entecavir is phosphorylated to its active triphosphate form, which then:
The antiviral effect begins within a few days of the first dose, with maximal viral suppression typically observed after several weeks of continued therapy. Because the drug is taken once daily, steady-state concentrations are reached after about 2 weeks of consistent use.
Baraclude is approved by the Hong Kong health authorities (aligned with FDA/EMA indications) for:
Treatment is intended for individuals with detectable HBV DNA and evidence of liver inflammation (elevated ALT) or fibrosis. Pediatric use is approved in some regions but is not the focus of this article.
Evidence from clinical studies suggests that entecavir may be useful in preventing hepatitis B reactivation in patients receiving:
These uses are not approved by regulatory agencies in Hong Kong and should only be considered under specialist supervision. Off-label therapy requires a careful risk-benefit assessment and close monitoring of liver function.
Regular follow-up appointments with a hepatologist or infectious disease specialist are essential for long-term management.
This article provides educational information about Baraclude and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes. Baraclude is a prescription medication, so you should carry a copy of the prescription and the pharmacy label. Keep the pills in their original container to avoid customs delays.
Baraclude 0.5 mg tablets are typically round, white, and bear the imprint “EN” on one side and the dosage “0.5 mg” on the other, though imprint details can vary by manufacturer.
The medication does not impair cognition or motor function in most patients. However, individuals who experience dizziness or severe fatigue should inform their aviation medical examiner, as safety-critical roles require stable performance.
Baraclude (entecavir) is a nucleoside analogue with a high genetic barrier to resistance, suitable for treatment-naïve patients. Tenofovir is a nucleotide analogue with a similar efficacy profile but different renal safety considerations. Choice of therapy depends on individual patient factors and physician judgment.
Large phase III trials demonstrated that entecavir achieved undetectable HBV DNA in >60 % of treatment-naïve patients after 48 weeks, with low rates of resistance. These results supported regulatory approval in Hong Kong and worldwide.
Baraclude is listed on the Hospital Authority’s formulary for chronic hepatitis B, subject to prescribing guidelines and patient eligibility criteria.
No. The tablet is formulated for whole-pill administration to ensure consistent absorption. Splitting may lead to dose variability and reduced effectiveness.
If kept in its original container at room temperature and protected from moisture, the pills remain stable until the printed expiration date. There is no specific “opened” shelf life separate from that date.
Brand-name Baraclude is generally priced higher than generic entecavir tablets of the same strength. Prices vary by pharmacy and insurance coverage; patients should discuss options with their healthcare provider or pharmacist.
Live vaccines (e.g., live-attenuated influenza) are not contraindicated, but the immune response may be slightly reduced in patients with chronic liver disease. Discuss vaccination timing with your physician.
